Emergent BioSolutions Inc. (EBS) Earnings

Management highlights

- Financial Position and Capital Allocation * Completed an April 2026 term loan refinancing that established a new $150 million term loan maturing in 2031, reduced interest rates, and improved operating and financial flexibility * The board of directors authorized a new $75 million debt repurchase program focused on senior unsecured notes, alongside an existing $50 million share repurchase program that runs through March 2027 * In Q2 2026, the company repurchased 1.1 million shares for ~$9 million, bringing year-to-date repurchases to 1.9 million shares for $18 million, with $37.5 million remaining available under the share repurchase authorization as of quarter end * By July 2026, the company had collected $145 million of the $190 million in accounts receivable outstanding at June 30, improving operating cash flow and liquidity * Capital allocation priorities balance debt reduction, disciplined share repurchases, and investments in international MCM growth, internal R&D, and external business development - Organizational and Operational Updates * Announced a business restructuring to reduce overall costs, improve operational efficiency, and align resourcing to current business needs; the restructuring is expected to deliver $40 million in annualized cost savings, with partial savings realized in 2026 and full run-rate savings achieved in 2027 * Unified internal R&D and business development into a single growth organization to enable faster, more data-driven portfolio decisions and more disciplined capital allocation, overseen by a central chief growth officer * The company is executing on a multi-year transformation plan while maintaining its core mission of protecting and saving lives against public health threats - Growth Strategy Priorities * 1) Expand international MCM orders and market opportunities * 2) Launch new Narcan line extensions, including a branded carrying case for Narcan nasal spray and multi-package configurations for high-volume users like first responders * 3) Drive organic growth through internal R&D programs including Tebexa, Ibonga, and Raxibacumab * 4) Pursue accelerated growth through selective, value-accretive external business development opportunities

Guidance

- Full-year 2026 total revenue guidance was revised downward to a range of $645 million to $675 million, from the prior guidance range of $720 million to $760 million. The downward revision is driven entirely by lower expected commercial segment revenue from Narcan, due to increased competitive and pricing pressure in the naloxone market; MCM guidance remains unchanged from prior outlooks. - Full-year 2026 GAAP net loss guidance is set at a range of -$245 million to -$225 million, which includes non-cash impairment charges for Narcan and restructuring-related expenses. - Adjusted net income guidance for 2026 is $10 million to $30 million, and adjusted EBITDA guidance was revised downward to $130 million to $150 million from the prior range of $155 million to $175 million. The proportional reduction in adjusted EBITDA is smaller than the revenue reduction due to partial offsets from the newly announced cost savings initiative and continued operating expense discipline. - Adjusted gross margin guidance for 2026 is 42% to 44%, reflecting the product mix impact of lower expected commercial revenue. - Third quarter 2026 total revenue guidance is set at a range of $110 million to $130 million, reflecting an expected pullback after accelerated MCM deliveries in the first half of the year and continued commercial segment pressure from the evolving naloxone market.

Segment performance

Emergent has two core operating segments: Medical Countermeasures (MCM) and Commercial. For the first half of 2026, MCM revenue was the primary driver of year-over-year total revenue growth, supported by accelerated product deliveries, earlier contract awards, and strong international sales, including a large one-time delivery of the BAT (Botulism Antitoxin) product that drove year-over-year gains in other revenue within the MCM segment. The Commercial segment, which is led by Narcan (naloxone), faced significant headwinds in the first half of 2026 due to increased competitive entry and pricing pressure in the broader naloxone market. Strong MCM performance offset weaker Commercial results to deliver a solid first half overall. As of Q2 2026 end, the company held $140 million in cash, $190 million in total liquidity, $590 million in gross debt, and a net leverage ratio of 1.9x trailing 12-month adjusted EBITDA, which remained stable year-over-year. Adjusted EBITDA for Q2 was $97 million with an adjusted gross margin of 41%.

Risks & headwinds

- The Narcan franchise faces growing competitive pressure from new generic entrants into the naloxone market, resulting in significant expected price erosion and lower-than-projected revenue for the balance of 2026 and beyond. While management expects Narcan to retain its brand leadership, competitive dynamics have driven a large downward revision to full-year guidance. - Global biosecurity risks are rising, including the potential for bad actors to use AI to develop dangerous new pathogens, creating new public health threats that require ongoing preparedness investment. - MCM revenue is dependent on timing of government procurement cycles and contract awards, which can create quarter-to-quarter and year-over-year revenue volatility.

Analyst Q&A

• Q: What initiatives will Emergent deploy to slow Narcan sales erosion, leverage the Narcan brand against new fentanyl analog threats, how has the R&D reorientation changed resource allocation, and what international MCM trends is the company seeing?

  A: Management will leverage Narcan's strong, well-recognized brand equity to retain market share, and is launching new innovations including branded carrying cases for students and multi-packs for high-volume first responder users. The R&D reorganization unifies internal R&D and business development to speed up decision making and improve capital discipline; core internal pipeline programs (Tebexa, Ibonga, Raxibacumab) will still receive continued investment. Emergent is seeing growing global demand for MCM preparedness, and is collaborating with AI industry leaders to help governments prepare for risks of AI-aided development of dangerous pathogens by bad actors.

• Q: What is driving the growth in other revenue, how competitive is the current naloxone market, and is the guidance revision entirely driven by Narcan headwinds?

  A: The main driver of year-over-year other revenue growth is a large, one-time delivery of Emergent's Botulism Antitoxin (BAT) product. Overall naloxone market demand remains stable (total unit volume is expected to be flat), but new generic entrants are driving significant price competition, and management expects additional price erosion going forward; Narcan will retain its leadership position but competitive pressure necessitated lower guidance. The entire guidance downward revision stems from lower expected commercial revenue from Narcan; MCM guidance remains unchanged from prior outlooks.

• Q: Is the $145 million July accounts receivable collection from normal operations, what is the pro forma cash balance, and what debt will the $75 million repurchase program target? When will the $40 million in cost savings be realized?

  A: The $145 million collection comes from normal working capital collection of Q2 2026 deliveries, and is not related to securitization or other financing. Most of the $145 million flowed through to the end-of-July cash balance, putting pro forma cash near ~$285 million before routine operating expenses. The $75 million debt repurchase authorization is specifically targeted at repurchasing the company's senior unsecured notes. Cost savings will begin being realized immediately in 2026, but the full $40 million annualized run-rate will be achieved starting in 2027.